肝癌术后辅助治疗中国专家共识(2023版)

Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma(2023 edition)

肝细胞癌(HCC)术后复发是影响患者术后长期生存的重要因素,目前尚无公认有效预防HCC术后复发转移的辅助治疗方案。以靶向药物、免疫检查点抑制剂为代表的系统抗肿瘤治疗和局部治疗单独或联合应用的辅助治疗策略正在积极探索中。肝癌术后辅助治疗中国专家共识协作组、中国医师协会外科医师分会、中国抗癌协会肝癌专业委员会、中华医学会肿瘤学分会肝癌学组组织相关领域专家,经过多次讨论、反复修订,最终形成《肝癌术后辅助治疗中国专家共识(2023版)》,旨在梳理HCC术后辅助治疗相关证据,结合临床实践,为临床医师开展术后辅助治疗提供更好的指导,提高HCC患者术后生存获益。

Recurrence of hepatocellular carcinoma(HCC)after surgery is an important factor affecting the long‐term postoperative survival of patients.So far,there is no proven postoperative adjuvant therapy to prevent HCC recurrence and metastasis.Currently,alone or in combination using of systemic antitumor therapy,represented by targeted drugs and immune checkpoint inhibitors,and local therapies are under active investigation.Alliance of Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma,Chinese College of Surgeons,Committee of Liver Cancer of Chinese Anti‐Cancer Association and Liver Cancer Group in Society of Oncology of Chinese Medical Association organize experts and scholars in related fields to discuss and revise for several times and finally formulate the Chinese Expert Consensus on Postoperative Adjuvant Therapy for Hepatocellular Carcinoma(2023 Edition),aiming to provide better guidance for clinicians to carry out postoperative adjuvant therapy on the basis of relevant evidence of HCC postoperative adjuvant therapy and clinical practice,so as to increase the survival benefits of HCC patients after surgery.